Browse
You are looking at 11 - 20 of 759 items
Search for other papers by Julia A Baran in
Google Scholar
PubMed
Search for other papers by Mya Bojarsky in
Google Scholar
PubMed
Search for other papers by Stephen Halada in
Google Scholar
PubMed
Search for other papers by Julio C Ricarte-Filho in
Google Scholar
PubMed
Search for other papers by Amber Isaza in
Google Scholar
PubMed
Search for other papers by Aime T Franco in
Google Scholar
PubMed
Search for other papers by Lea F Surrey in
Google Scholar
PubMed
Search for other papers by Tricia Bhatti in
Google Scholar
PubMed
Search for other papers by Zubair Baloch in
Google Scholar
PubMed
Search for other papers by N Scott Adzick in
Google Scholar
PubMed
Division of Oncology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
Search for other papers by Sogol Mostoufi-Moab in
Google Scholar
PubMed
Department of Otorhinolaryngology: Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Search for other papers by Ken Kazahaya in
Google Scholar
PubMed
Search for other papers by Andrew J Bauer in
Google Scholar
PubMed
Objective
The American Thyroid Association (ATA) Pediatric Guidelines recommend selective, prophylactic central neck dissection (pCND) for patients with papillary thyroid carcinoma (PTC) based on tumor focality, tumor size, and the surgeon’s experience. With the expansion of pre-surgical somatic oncogene testing and continued controversy over the benefits of pCND, oncogenic alteration data may provide an opportunity to stratify pCND. This study compared lymph node (LN) involvement in pediatric patients with PTC between tumors with low- and high-invasive-associated alterations to explore the potential utility of preoperative oncogenic alterations in the stratification of pCND.
Methods
This is retrospective cohort study of pediatric patients who underwent somatic oncogene testing post thyroidectomy for PTC between July 2003 and July 2022.
Results
Of 192 eligible PTC patients with postoperative somatic oncogene data, 19 tumors harbored somatic alterations associated with low-invasive disease (19/192, 10%), and 128 tumors harbored a BRAFV600E alteration (45/192, 23%) or an oncogenic fusion (83/192, 43%). Tumors with low-invasive alterations were less likely to present malignant preoperative cytology (2/18, 11%) than those with high-invasive alterations (97/124, 78%; P < 0.001). Twelve patients with low-invasive alterations had LNs dissected from the central neck (12/19, 63%) compared to 127 patients (127/128, 99%) with high-invasive alterations. LN metastasis was identified in two patients with low-invasive alterations (2/19, 11%) compared to 107 patients with high-invasive alterations (107/128, 84%; P < 0.001).
Conclusion
Pediatric patients with low-invasive somatic oncogenic alterations are at low risk for metastasis to central neck LNs. Our findings suggest that preoperative knowledge of somatic oncogene alterations provides objective data to stratify pediatric patients who may not benefit from pCND.
UMR 9019 CNRS F-94805 Villejuif, France
Gustave Roussy, Villejuif, France
Search for other papers by Fabio Hecht in
Google Scholar
PubMed
UMR 9019 CNRS F-94805 Villejuif, France
Gustave Roussy, Villejuif, France
Search for other papers by Laura Valerio in
Google Scholar
PubMed
UMR 9019 CNRS F-94805 Villejuif, France
Gustave Roussy, Villejuif, France
Search for other papers by Carlos Frederico Lima Gonçalves in
Google Scholar
PubMed
UMR 9019 CNRS F-94805 Villejuif, France
Gustave Roussy, Villejuif, France
Search for other papers by Marylin Harinquet in
Google Scholar
PubMed
Search for other papers by Rabii Ameziane El Hassani in
Google Scholar
PubMed
Search for other papers by Denise P Carvalho in
Google Scholar
PubMed
Gustave Roussy, Villejuif, France
Sorbonne Université, Paris, France
Search for other papers by Stephane Koundrioukoff in
Google Scholar
PubMed
Search for other papers by Jean-Charles Cadoret in
Google Scholar
PubMed
UMR 9019 CNRS F-94805 Villejuif, France
Gustave Roussy, Villejuif, France
Search for other papers by Corinne Dupuy in
Google Scholar
PubMed
Objective
Ionizing radiation generates genomic instability by promoting the accumulation of chromosomal rearrangements. The oncogenic translocation RET/PTC1 is present in more than 70% of radiation-induced thyroid cancers. Both RET and CCDC6, the genes implicated in RET/PTC1, are found within common fragile sites – chromosomal regions prone to DNA breakage during slight replication stress. Given that irradiated cells become more susceptible to genomic destabilization due to the accumulation of replication-stress-related double-strand breaks (DSBs), we explored whether RET and CCDC6 exhibit DNA breakage under replicative stress several days post-irradiation of thyroid cells.
Methods
We analyzed the dynamic of DNA replication in human thyroid epithelial cells (HThy-ori-3.1) 4 days post a 5-Gy exposure using molecular DNA combing. The DNA replication schedule was evaluated through replication-timing experiments. We implemented a ChIP-qPCR assay to determine whether the RET and CCDC6 genes break following irradiation.
Results
Our study indicates that replicative stress, occurring several days post-irradiation in thyroid cells, primarily causes DSBs in the RET gene. We discovered that both the RET and CCDC6 genes undergo late replication in thyroid cells. However, only RET’s replication rate is notably delayed after irradiation.
Conclusion
The findings suggest that post-irradiation in the RET gene causes a breakage in the replication fork, which could potentially invade another genomic area, including CCDC6. As a result, this could greatly contribute to the high prevalence of chromosomal RET/PTC rearrangements seen in patients exposed to external radiation.
Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China
Search for other papers by Haiyang Zhang in
Google Scholar
PubMed
Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China
Search for other papers by Shuo Wu in
Google Scholar
PubMed
Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China
Search for other papers by Shuyu Hu in
Google Scholar
PubMed
Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China
Search for other papers by Xianqun Fan in
Google Scholar
PubMed
Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China
Search for other papers by Xuefei Song in
Google Scholar
PubMed
Search for other papers by Tienan Feng in
Google Scholar
PubMed
Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China
Search for other papers by Huifang Zhou in
Google Scholar
PubMed
Background
Thyroid eye disease (TED) is an autoimmune orbital disease, with intravenous glucocorticoid (IVGC) therapy as the first-line treatment. Due to uncertain response rates and possible side effects, various prediction models have been developed to predict IVGC therapy outcomes.
Methods
A thorough search was conducted in PubMed, Embase, and Web of Science databases. Data extraction included publication details, prediction model content, and performance. Statistical analysis was performed using R software, including heterogeneity evaluation, publication bias, subgroup analysis, and sensitivity analysis. Forest plots were utilized for result visualization.
Results
Of the 12 eligible studies, 47 prediction models were extracted. All included studies exhibited a low-to-moderate risk of bias. The pooled area under the receiver operating characteristic curve (AUC) and the combined sensitivity and specificity for the models were 0.81, 0.75, and 0.79, respectively. In view of heterogeneity, multiple meta-regression and subgroup analysis were conducted, which showed that marker and modeling types may be the possible causes of heterogeneity (P < 0.001). Notably, imaging metrics alone (AUC = 0.81) or clinical characteristics combined with other markers (AUC = 0.87), incorporating with multivariate regression (AUC = 0.84) or radiomics analysis (AUC = 0.91), yielded robust and reliable prediction outcomes.
Conclusion
This meta-analysis comprehensively reviews the predictive models for IVGC therapy response in TED. It underscores that integrating clinical characteristics with laboratory or imaging indicators and employing advanced techniques like multivariate regression or radiomics analysis significantly enhance the efficacy of prediction. Our research findings offer valuable insights that can guide future studies on prediction models for IVGC therapy in TED.
Search for other papers by Yasuhiro Ito in
Google Scholar
PubMed
Search for other papers by Akira Miyauchi in
Google Scholar
PubMed
Papillary and follicular thyroid carcinomas (PTC and FTC) are prominent malignancies that originate from thyroid follicular cells. PTC is usually diagnosed via preoperative cytology, and large tumor size, clinical node metastasis, and distant metastasis constitute preoperative prognostic factors. Gross extrathyroidal and extranodal tumor extensions have a significant prognostic impact, are evaluated intraoperatively, and are useful for determining the extent of surgery. Aggressive variants, such as tall cell and hobnail variants, a high Ki-67 labeling index (LI), and somatic gene mutations are prognostic factors in postoperative pathological and molecular examinations. In contrast, FTC is generally diagnosed based on the postoperative pathology. Large tumor size and M factors have prognostic value; however, the findings of pathological examinations are very important. FTCs are classified as minimally invasive, encapsulated angioinvasive, and widely invasive FTCs. Widely invasive FTC with vascular invasion (VI) and encapsulated angioinvasive FTCs with extensive VI have a poor prognosis, whereas widely invasive FTC without VI has an excellent prognosis, which is similar to that of minimally invasive FTC. This indicates that VI is a considerably more important prognostic marker than capsular invasion. For postoperative follow-up, dynamic markers such as the thyroglobulin-doubling rate (DR), metastatic tumor volume-DR, and change in neutrophil-to-lymphocyte ratio are important and are useful for evaluating the effectiveness of treatments, such as radioactive iodine therapy and molecular targeted therapy, for recurrent lesions. For clinicians, it is important to accurately evaluate prognostic markers of PTC and FTC in the pre-, intraoperative, and postoperative phases.
Search for other papers by Andrea Leoncini in
Google Scholar
PubMed
Search for other papers by Chiara Camponovo in
Google Scholar
PubMed
Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland
Search for other papers by Gaetano Paone in
Google Scholar
PubMed
Search for other papers by Elena Gamarra in
Google Scholar
PubMed
Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland
Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
Search for other papers by Giorgio Treglia in
Google Scholar
PubMed
Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland
Search for other papers by Pierpaolo Trimboli in
Google Scholar
PubMed
Objective
Thyroid nodule (TN) is usually managed according to Thyroid Imaging And Reporting Data Systems (TIRADS) with the major aim to reduce as much as possible unnecessary fine-needle aspiration cytologies (UN-FNACs). Since the assessment of autonomously functioning thyroid nodule (AFTN) according to TIRADS is heterogeneous, that virtually benign entity may increase the rate of UN-FNAC. This study retrospectively analyzed the appropriateness of TIRADS-based FNAC indication in AFTNs, also looking at the impact of TSH and nodule size.
Methods
Cases diagnosed with AFTN on scintigraphy were searched. Patients who had undergone AFTN treatment, were on medications or supplementation that could affect thyroid function, or had multiple AFTNs were excluded. The AFTNs were assessed according to ACR-TIRADS.
Results
Forty-eight AFTNs were included of which 37.5% had FNAC indication according to TIRADS. The FNAC indication rate in the case of TSH lower than 0.4 mIU/L was significantly higher than in other cases (P = 0.0078). The most accurate TSH cut-off and AFTN size associated with UN-FNAC were ≤ 0.41 mIU/L and > 22 mm, respectively. The multivariate analysis showed that both TSH and nodule size were independent predictors of UN-FNAC with OR of 6.65 and 6.46, respectively. According to these data, the rate of FNAC indication dropped to 4.16%.
Conclusion
Inappropriate FNACs in AFTNs are primarily observed in patients with low TSH and large AFTN. Since these cases typically undergo scintigraphy, the risk of TIRADS-based UN-FNAC is clinically negligible. There is no need for integrating other imaging procedures into the TIRADS model.
Department of Nuclear Medicine, The Fourth hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Search for other papers by Zhaoqi Zhang in
Google Scholar
PubMed
Search for other papers by Josef Yu in
Google Scholar
PubMed
Search for other papers by Eva Rainer in
Google Scholar
PubMed
Search for other papers by Lindsay Hargitai in
Google Scholar
PubMed
Search for other papers by Zewen Jiang in
Google Scholar
PubMed
Search for other papers by Georgios Karanikas in
Google Scholar
PubMed
Search for other papers by Tatjana Traub-Weidinger in
Google Scholar
PubMed
Search for other papers by Richard Crevenna in
Google Scholar
PubMed
Search for other papers by Marcus Hacker in
Google Scholar
PubMed
Search for other papers by Shuren Li in
Google Scholar
PubMed
Objective
Correct diagnosis and prognostic evaluation of medullary thyroid cancer (MTC) are crucial to treat patients. The purpose of this study was to evaluate the diagnostic and prognostic value of [18F]F-DOPA PET/CT in patients with MTC.
Methods
We reviewed MTC patients who underwent [18F]F-DOPA PET/CT from June 2008 to November 2023. Clinical characteristics, follow-up data, and the following [18F]F-DOPA PET/CT parameters were recorded: maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), and SUVmean of multiple organs. The diagnostic value of PET/CT for the detection of tumor lesions was calculated. Serum basal calcitonin (bCt) and stimulated calcitonin (sCt) were determined. Receiver operating characteristics, Kaplan–Meier, and Cox regression analyses were performed.
Results
In total, 109 patients (50 women, 59 men; average age, 55 ± 14 years) were included in the analysis. The patient-related sensitivity, specificity, and accuracy of [18F]F-DOPA PET/CT were 95%, 93%, and 94%, respectively. The lesion-related sensitivity, specificity, and accuracy were 65%, 99%, and 72%, respectively. The optimal cutoff values of bCt, sCt, and CEA to obtain positive [18F]F-DOPA PET/CT results were 64 pg/mL, 1808 pg/mL, and 4 µg/L, respectively. Patients with negative [18F]F-DOPA PET/CT had longer overall survival than patients with positive [18F]F-DOPA PET/CT results (P = 0.017). Significant positive correlations were found between bCt, sCt, and CEA with SUVmax, SUVmean, and MTV of [18F]F-DOPA PET/CT (P < 0.001). [18F]F-DOPA PET/CT results and MTV may be useful for the evaluation of the prognosis of patients with recurrent MTC, while age and MTV were independent prognostic factors in patients with primary MTC. For all patients, SUVmean of the left kidney, liver, aorta, and pancreas might be used to independently predict OS.
Conclusion
[18F]F-DOPA PET/CT had great value for diagnosis and prognostic assessment in patients with MTC. The DOPA PET/CT parameter SUVmean and MTV showed significant association with OS.
Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Korea
Search for other papers by Chae Won Chung in
Google Scholar
PubMed
Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Search for other papers by Kyungsik Kim in
Google Scholar
PubMed
Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Integrated Major in Innovative Medical Science, Seoul National University College of Medicine, Seoul, Korea
Search for other papers by Sue K Park in
Google Scholar
PubMed
Search for other papers by Dal Lae Ju in
Google Scholar
PubMed
Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea
Search for other papers by Young Joo Park in
Google Scholar
PubMed
Search for other papers by Choong Ho Shin in
Google Scholar
PubMed
Search for other papers by Jong Kwan Jun in
Google Scholar
PubMed
Search for other papers by June-Key Chung in
Google Scholar
PubMed
Search for other papers by Yoon Ju Song in
Google Scholar
PubMed
Search for other papers by Young Ah Lee in
Google Scholar
PubMed
Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea
Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea
Search for other papers by Gi Jeong Cheon in
Google Scholar
PubMed
Search for other papers by Sun Wook Cho in
Google Scholar
PubMed
Objective
This study aimed to assess selenium status in South Korean pregnant women and its impact on maternal thyroid function and pregnancy outcomes.
Methods
‘Ideal Breast Milk (IBM) Cohort Study’ included 367 pregnant women out of 442 participants and categorized into three groups based on plasma selenium levels: deficient (< 70 μg/L), suboptimal (70–99 μg/L), and optimal (≥ 100 μg/L). During the second or third trimester, various blood parameters, including selenium, thyroid-stimulating hormone, free T4, free T3, and anti-thyroid peroxidase antibody levels, were measured. Thyroid parenchymal echogenicity was assessed as another surrogate marker for thyroid autoimmunity using ultrasonography.
Results
The median plasma selenium was 98.8 (range: 46.7–206.4) μg/L, and 30 individuals (8%) were categorized as deficient, while 164 (45%) were classified in the suboptimal group. Selenium deficiency was associated with markers of autoimmune thyroiditis, including positive anti-thyroid peroxidase antibody results (13.3 (deficient) vs 4.6 (optimal) %, P = 0.031) and thyroid parenchymal heterogeneity on ultrasound (33.3 (deficient) vs 14.6 (suboptimal) vs 17.3 (optimal) %, P = 0.042), independently of gestational age. The incidence of severe preeclampsia was higher in the group not taking selenium supplements, particularly among those with twin pregnancies, compared to the group taking selenium supplements (0 (selenium supplement) vs 9.0 (no supplement) %, P = 0.015).
Conclusion
Pregnant women experience mild selenium deficiency, which can lead to significant health issues including maternal thyroid autoimmunity and obstetrical complications during pregnancy. Guidelines for appropriate selenium intake according to the stage of pregnancy and the number of fetuses are needed.
Search for other papers by Hideyuki Imai in
Google Scholar
PubMed
Search for other papers by Natsuko Watanabe in
Google Scholar
PubMed
Search for other papers by Rei Hirose in
Google Scholar
PubMed
Search for other papers by Masakazu Koshibu in
Google Scholar
PubMed
Search for other papers by Masahiro Ichikawa in
Google Scholar
PubMed
Search for other papers by Akiko Sankoda in
Google Scholar
PubMed
Search for other papers by Shigenori Hiruma in
Google Scholar
PubMed
Search for other papers by Nami Suzuki in
Google Scholar
PubMed
Search for other papers by Masako Matsumoto in
Google Scholar
PubMed
Search for other papers by Miho Fukushita in
Google Scholar
PubMed
Search for other papers by Ai Yoshihara in
Google Scholar
PubMed
Search for other papers by Jaeduk yoshimura Noh in
Google Scholar
PubMed
Search for other papers by Kiminori Sugino in
Google Scholar
PubMed
Search for other papers by Koichi Ito in
Google Scholar
PubMed
Objective: There are few reports of subacute thyroiditis (SAT) during pregnancy. This study aimed to clarify the clinical characteristics of SAT in pregnant patients. Methods and results: Seven patients diagnosed with SAT during pregnancy at our institution from January 2004 to December 2021 were identified, and their clinical findings were retrospectively examined. At SAT diagnosis, the median age was 34 [range 31-42] years, the median duration of pregnancy was 5 [4-24] weeks, and all patients had neck pain but no fever. On laboratory examination, median (range) free thyroxine, free triiodothyronine, and C-reactive protein levels were 2.66 (1.14-7.77) ng/dL, 7.1 (3.3-16.1) pg/mL, and 2.22 (0.42-5.79) mg/dL, respectively, and all patients had a hypoechoic lesion of the thyroid gland. Three patients (43%) were treated with steroids, and 3 patients (43%) received replacement therapy with levothyroxine for hypothyroidism following destructive thyroiditis. There were no pregnancy complications in any of the cases. These 7 patients (pregnancy group) were compared with 217 non-pregnant female patients (non-pregnancy group) aged 31 to 42 years who were diagnosed with SAT at our institution from 2016 to 2019. The frequency of body temperatures above 37°C was lower in the pregnancy group than in the non-pregnancy group (0% vs. 65%). Conclusion: Patients who develop SAT during pregnancy may have less fever than non-pregnant patients with SAT. There were no pregnancy complications in the pregnancy group in this study. This suggests that adverse pregnancy outcomes may be avoided by appropriate management of SAT, including hypothyroidism after destructive thyroiditis.
University Center of João Pessoa – UNIPE, João Pessoa, PB, Brazil
Search for other papers by Fabyan Esberard de Lima Beltrão in
Google Scholar
PubMed
Post-Graduation Program in Cognitive Neuroscience and Behavior, Psychology Department of the Center of Human Sciences, Federal University of Paraíba, João Pessoa, Paraíba, Brazil
Search for other papers by Daniele Carvalhal de Almeida Beltrão in
Google Scholar
PubMed
Search for other papers by Giulia Carvalhal in
Google Scholar
PubMed
Search for other papers by Fabyanna Lethicia de Lima Beltrão in
Google Scholar
PubMed
Search for other papers by Jocyel de Brito Oliveira in
Google Scholar
PubMed
Search for other papers by Hatilla dos Santos Silva in
Google Scholar
PubMed
Search for other papers by Helena Mariana Pitangueira Teixeira in
Google Scholar
PubMed
Search for other papers by Juliana Lopes Rodrigues in
Google Scholar
PubMed
Search for other papers by Camila Alexandrina Viana de Figueiredo in
Google Scholar
PubMed
Search for other papers by Ryan dos Santos Costa in
Google Scholar
PubMed
Search for other papers by Fabio Hecht in
Google Scholar
PubMed
Search for other papers by Giciane Carvalho Vieira in
Google Scholar
PubMed
Search for other papers by Maria da Conceição Rodrigues Gonçalves in
Google Scholar
PubMed
Search for other papers by Antonio C. Bianco in
Google Scholar
PubMed
Postgraduate Program in Interactive Processes of Organs and Systems, Health & Science Institute, Federal University of Bahia, Salvador, BA, Brazil
Search for other papers by Helton Estrela Ramos in
Google Scholar
PubMed
Introduction
The type 2 deiodinase and its Thr92Ala-DIO2 polymorphism have been linked to clinical outcomes in acute lung injury and coronavirus disease 2019 (COVID-19).
Objective
The objective was to identify a potential association between Thr92Ala-DIO2 polymorphism and body composition (appendicular muscle mass, myosteatosis, and fat distribution) and to determine whether they reflect the severity or mortality associated with the disease.
Methods
In this prospective cohort study (June–August 2020), 181 patients hospitalized with moderate-to-severe COVID-19 underwent a non-contrast-enhanced computed tomography (CT) of the thorax to assess body composition, laboratory tests, and genotyping for the Thr92Ala-DIO2 polymorphism.
Results
In total, 181 consecutive patients were stratified into three subgroups according to the genotype: Thr/Thr (n = 64), Thr/Ala (n = 96), and Ala/Ala (n = 21). The prevalence of low muscle area (MA) (< 92 cm²) was 52.5%. Low MA was less frequent in Ala/Thr patients (44.8%) than in Thr/Thr (60.9%) or Ala/Ala patients (61.9%) (P = 0.027). Multivariate logistic regression analysis confirmed that the Thr/Ala allele was associated with a reduced risk of low MA (41% to 69%) and myosteatosis (62% to 72%) compared with Thr/Thr + Ala/Ala (overdominant model). Kaplan–Meier curves showed that patients with low muscle mass and homozygosity had lower survival rates than the other groups. Notably, the heterozygotes with MA ≥92 cm² exhibited the best survival rate.
Conclusion
Thr92Ala-DIO2 heterozygosity is associated with increased skeletal MA and less myosteatosis in patients with COVID-19. The protective effect of Thr92Ala-DIO2 heterozygosity on COVID-19 mortality is restricted to patients with reduced MA.
Search for other papers by Bernard Goichot in
Google Scholar
PubMed
Search for other papers by François Lefebvre in
Google Scholar
PubMed
Search for other papers by Stéphane Vinzio in
Google Scholar
PubMed
Search for other papers by Anne Cailleux in
Google Scholar
PubMed
Search for other papers by Jean-Marc Kuhn in
Google Scholar
PubMed
Search for other papers by Olivier Schneegans in
Google Scholar
PubMed
Search for other papers by Bodgan Catargi in
Google Scholar
PubMed
Search for other papers by Olivier Gilly in
Google Scholar
PubMed
Search for other papers by Philippe Baltzinger in
Google Scholar
PubMed
Search for other papers by Nicolas Meyer in
Google Scholar
PubMed
Search for other papers by Philippe Caron in
Google Scholar
PubMed
Objective: Subclinical hyperthyroidism (SCH) is common and associated with atrial fibrillation (AF) risk in the elderly. Current guidelines rely on a low level of evidence.
Methods: Randomized clinical trial including patients 50 years and older, with TSH <0.4 mU/L and normal thyroid hormone concentrations. All patients showed autonomy on thyroid scan. They were randomized either to receive radioiodine (I131) or to be monitored and treated only if they underwent AF or evolved towards overt hyperthyroidism. Primary outcome was the onset of new AF. Secondary outcomes were treatment-induced hypothyroidism rate and health-related quality of life.
Results: 144 patients (mean age 65.3±8.9y, 76% female) were randomized, 74 to surveillance and 70 to treatment. Four patients in the surveillance group and one in the treatment group developed AF (p=0.238). However, the patient who developed AF in the treatment group maintained TSH <0.4 mU/L at AF onset. A post-hoc analysis was carried out and showed that when normalization of TSH was considered, the risk of AF was significantly reduced (p=0.0003). In the surveillance group, several patients showed no classical characteristics associated with AF risk, including age>65y or TSH<0.1mU/L. Of 94 patients treated using radioiodine, 25% developed hypothyroidism during follow-up.
Conclusions: Due to recruitment difficulties this study failed to demonstrate that SCH treatment can reduce significantly the incidence of AF in patients older than 50 years with thyroid autonomy even if all the patients who developed AF maintained TSH <0.4 mU/L. This result must be balanced with the increased risk of radioiodine-induced hypothyroidism.
